Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: The Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study

被引:15
作者
Engelberger, Rolf P. [1 ,2 ,3 ]
Noll, Georg [4 ]
Schmidt, Dominique
Alatri, Adriano [1 ]
Frei, Benedikt
Kaiser, Walter E. [5 ]
Kucher, Nils [2 ,3 ,6 ]
机构
[1] CHU Vaudois, Div Angiol, CH-1011 Lausanne, Switzerland
[2] Inselspital Bern, Univ Hosp, Swiss Cardiovasc Ctr, Clin Angiol, Bern, Switzerland
[3] Univ Bern, CH-3012 Bern, Switzerland
[4] Klin Hirslanden, HerzKlin, Zurich, Switzerland
[5] DocWorld AG, Menzingen, Switzerland
[6] Univ Hosp, Inselspital, Swiss Cardiovasc Ctr, Clin Cardiol, Bern, Switzerland
关键词
Atrial fibrillation; Primary care; Rivaroxaban; Stroke prevention; Treatment satisfaction; STROKE PREVENTION; ANTITHROMBOTIC THERAPY; TREATMENT SATISFACTION; ORAL ANTICOAGULATION; WARFARIN; RISK; DABIGATRAN; ADHERENCE; MANAGEMENT; PHYSICIANS;
D O I
10.1016/j.ejim.2015.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known. Methods: Prospective data collection by 115 primary care physicians in Switzerland on consecutive nonvalvular AF patients with newly established rivaroxaban anticoagulation with 3-month follow-up. Results: We enrolled 537 patients (73 +/- 11 years, 57% men) with mean CHADS2 and HAS-BLED-scores of 2.2 +/- 1.3 and 2.4 +/- 1.1, respectively: 301(56%) were switched from VKA to rivaroxaban (STR-group) and 236(44%) were VKA-naive (VN-group). Absence of routine coagulation monitoring (68%) and fixed-dose once-daily treatment (58%) were the most frequent criteria for physicians to initiate rivaroxaban. In the STR-group, patient's satisfaction increased from 3.6 +/- 1.4 under VKA to 5.5 +/- 0.8 points (P < 0.001), and overall physician satisfaction from 3.9 +/- 1.3 to 5.4 +/- 0.9 points (P < 0.001) at 3months of rivaroxaban therapy (score from 1 to 6 with higher scores indicating greater satisfaction). In the VN-group, both patient's (5.4 +/- 0.9) and physician's satisfaction (5.5 +/- 0.7) at follow-up were comparable to the STR-group. During follow-up, 1(0.19%; 95% CI, 0.01-1.03%) ischemic stroke, 2(0.37%; 95% CI, 0.05-1.34%) major non-fatal bleeding and 11(2.05%; 95% CI, 1.03-3.64%) minor bleeding complications occurred. Rivaroxaban was stopped in 30(5.6%) patients, with side effects being the most frequent reason. Conclusion: Initiation of rivaroxaban for patients with nonvalvular AF by primary care physicians was associated with a low clinical event rate and with high overall patient's and physician's satisfaction. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:508 / 514
页数:7
相关论文
共 50 条
  • [31] Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Martinez, Brandon K.
    Baker, William L.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Meinecke, Anna-Katharina
    Eriksson, Daniel
    Coleman, Craig, I
    PHARMACOTHERAPY, 2019, 39 (02): : 196 - 203
  • [32] Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation The NAXOS Study
    Van Ganse, Eric
    Danchin, Nicolas
    Mahe, Isabelle
    Hanon, Olivier
    Jacoud, Flore
    Nolin, Maeva
    Dalon, Faustine
    Lefevre, Cinira
    Cotte, Francois-Emery
    Gollety, Sabrina
    Falissard, Bruno
    Belhassen, Manon
    Steg, Ph. Gabriel
    STROKE, 2020, 51 (07) : 2066 - 2075
  • [33] Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study
    Barrios, Vivencio
    Escobar, Carlos
    Prieto, Luis
    Osorio, Genoveva
    Polo, Jose
    Maria Lobos, Jose
    Vargas, Diego
    Garcia, Nicolas
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (09): : 769 - 776
  • [34] Comparison of Three Methods of Antithrombotic Therapy in Elderly Patients With Nonvalvular Atrial Fibrillation
    Shevelev, V. I.
    Kanorsky, S. G.
    KARDIOLOGIYA, 2012, 52 (07) : 56 - 60
  • [35] Trough Concentration Deficiency of Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events
    Gao, Hongjin
    Li, Yumei
    Sun, Hong
    Huang, Xiufang
    Chen, Hui
    Lin, Wei
    Chen, Min
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 80 (06) : 869 - 876
  • [36] Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation
    Providencia, Rui
    Marijon, Eloi
    Albenque, Jean-Paul
    Combes, Stephane
    Combes, Nicolas
    Jourda, Francois
    Hireche, Hassiba
    Morais, Joao
    Boveda, Serge
    EUROPACE, 2014, 16 (08): : 1137 - 1144
  • [37] A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk
    Liu, Penghui
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [38] Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation: Has Prescribing Improved?
    Bista, Durga
    Chalmers, Leanne
    Peterson, Gregory M.
    Bereznicki, Luke R. E.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2017, 23 (06) : 573 - 578
  • [39] Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
    Chan, Kevin E.
    Edelman, Elazer R.
    Wenger, Julia B.
    Thadhani, Ravi I.
    Maddux, Franklin W.
    CIRCULATION, 2015, 131 (11) : 972 - 979
  • [40] Switching of oral anticoagulants in patients with nonvalvular atrial fibrillation: A narrative review
    Kefale, Adane Teshome
    Peterson, Gregory M.
    Bezabhe, Woldesellassie M.
    Bereznicki, Luke R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (02) : 514 - 534